The STRIDE study did not meet its primary or secondary efficacy endpoint
The company to suspend mavodelpar development and implement a workforce reduction
https://www.globenewswire.com/news-release/2023/12/14/2796344/0/en/Reneo-Pharmaceuticals-Announces-Results-from-Pivotal-STRIDE-Study-of-Mavodelpar-in-Primary-Mitochondrial-Myopathies-PMM.html
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.